期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Nobiletin Prevents Body Weight Gain and Bone Loss in Ovariectomized C57BL/6J Mice 被引量:2
1
作者 Young-Sil Lee Midori Asai +5 位作者 Sun-Sil Choi takayuki yonezawa Toshiaki Teruya Kazuo Nagai Je-Tae Woo Byung-Yoon Cha 《Pharmacology & Pharmacy》 2014年第10期959-965,共7页
Obesity and osteoporosis are associated with estrogen deficiency following menopause. Therefore, it is important to prevent and treat both disorders to maintain a healthy life in postmenopausal women. Nobiletin, a pol... Obesity and osteoporosis are associated with estrogen deficiency following menopause. Therefore, it is important to prevent and treat both disorders to maintain a healthy life in postmenopausal women. Nobiletin, a polymethoxylated flavone, exhibits various pharmacologic effects, including anti-tumor and anti-inflammatory activities. Therefore, in this study, we examined the effects of nobiletin on obesity, obesity-related metabolic disorders, and bone mass in ovariectomized (OVX) mice. Mice were divided into four groups and underwent sham operation or OVX. OVX mice were treated with 50 or 100 mg/kg nobiletin, or received vehicle alone (0.3% carboxyl methyl cellulose/0.5% dimethyl sulfoxide). Nobiletin decreased body weight gain and white adipose tissue weight in OVX mice. Nobiletin also decreased triglyceride levels, and tended to reduce plasma total cholesterol and glucose levels. Additionally, nobiletin prevented the reduction in bone mineral density of the trabecular region of the femur in OVX mice. Taken together, our results suggest that nobiletin improves adiposity, dyslipidemia, hyperglycemia, and prevents bone loss in OVX mice. Therefore, nobiletin is expected to have beneficial effects for the prevention and improvement of metabolic disorders and osteoporosis in postmenopausal women. 展开更多
关键词 NOBILETIN OVARIECTOMY Obesity LIPID and GLUCOSE Metabolism Bone MINERAL Density
下载PDF
Antiproliferative Activity of Acerogenin C, a Macrocyclicdiarylheptanoid, on PDGF-Induced Human Aortic Smooth Muscle Cells Proliferation
2
作者 Byung-Yoon Cha Wen Lei Shi +7 位作者 Kotaro Watanabe takayuki yonezawa Toshiaki Teruya Kiyotake Kiyotake Yuichi Ishikawa Shigeru Nishiyama Kazuo Nagai Je-Tae Woo 《Pharmacology & Pharmacy》 2015年第2期47-55,共9页
Platelet-derived growth factor (PDGF)-BB is one of the most potent factors in the development and progression of various vascular disorders, such as atherosclerosis and restenosis. PDGF is a major stimulant for vascul... Platelet-derived growth factor (PDGF)-BB is one of the most potent factors in the development and progression of various vascular disorders, such as atherosclerosis and restenosis. PDGF is a major stimulant for vascular smooth muscle cells (VSMCs) proliferation via the mitogenesis signaling pathway. In the present study, we investigated the effect of acerogenin C, a macrocyclicdiarylhep-tanoid, on PDGF-BB-stimulated human aortic smooth muscle cells (HASMCs) proliferation. Acer-ogenin C significantly inhibited PDGF (20 ng/mL)-BB-induced [3H]-thymidine incorporation into DNA at concentrations of 0.1, 1 and 10 μM without any cytotoxicity. Acerogenin C also blocked PDGF-BB-stimulated phosphorylation of PLCγ1 and Akt but had no effect on extracellular signal-regulated kinase 1/2 (ERK1/2) and PDGF beta-receptor (Rβ) activation. In addition, acerogenin C (0.1 - 10 μM) induced cell-cycle arrest in the G1 phase, which was associated with the down-regulation of cyclins and the up-regulation of p27kip1. These results suggest that acerogenin C blocks PDGF-BB-stimulated HASMCs proliferation via G0/G1 arrest in association with the induction of p27kip1 and the suppression of PLCγ1 and phosphatidylinositol 3-kinase (PI3-K)/Akt signaling pathways. Furthermore, acerogenin C may be used for prevention and treatment of atherosclerosis during restenosis after coronary angioplasty. 展开更多
关键词 HASMCs Acerogenin C PDGF-BB P27KIP1 CELL CYCLE
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部